Related Experiment Video
Updated: Jun 4, 2026

Biological Preparation and Mechanical Technique for Determining Viscoelastic Properties of Zonular Fibers
Published on: December 16, 2021
[Clinical aspects of Marfan syndrome]
Tina Zimmermann Belsing1, Allan Meldgaard Lund, Lars Søndergaard
1Kildegårdsvej 16 B, 2. tv., Hellerup, Denmark. t.z.belsing@dadlnet.dk
Abstract:
Marfan syndrome (MFS) and MFS-related diseases are inherited connective tissue disorders involving several organ systems. The diagnosis of MFS is difficult as the many symptoms overlap with those of other systemic connective tissue diseases. The phenotype is progressive. Effective surgical therapy and standardized follow-up programs have led to an improved lifespan for the affected individuals. Selective angiotensin II, type 1 (AT1) blockers may improve several manifestations of MFS, but the outcome of clinical trials is presently unknown. This review describes the importance of a coordinated strategy for diagnosis, treatment and follow-up.
Insights
Marfan syndrome (MFS) is a complex inherited connective tissue disorder. A coordinated approach to diagnosis, treatment, and follow-up is crucial for improving patient outcomes and lifespan.
Area of Science:
- Genetics and Medicine
- Connective Tissue Diseases
- Cardiovascular Medicine
Context:
- Marfan syndrome (MFS) and related disorders are inherited connective tissue diseases affecting multiple organ systems.
- Diagnosis is challenging due to overlapping symptoms with other systemic connective tissue diseases.
- The progressive nature of the MFS phenotype necessitates careful management.
Purpose:
- To review the diagnostic challenges and current management strategies for Marfan syndrome.
- To highlight the importance of a coordinated approach in the diagnosis, treatment, and follow-up of MFS patients.
- To discuss potential therapeutic advancements, including the role of angiotensin II type 1 blockers.
Summary:
- MFS diagnosis is complex due to symptom overlap and progressive nature.
- Improved lifespan is attributed to surgical interventions and standardized follow-up.
- Angiotensin II type 1 blockers show potential but require further clinical trial validation.
Impact:
- Establishes the need for integrated care strategies in Marfan syndrome management.
- Provides a foundation for future research into MFS pathogenesis and treatment.
- Aims to improve the quality of life and long-term prognosis for individuals with MFS.
Related Concept Videos
Aneurysm I: Introduction
Mitral Stenosis II: Clinical features and Diagnostic Tests
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Coronary Artery Disease III: Clinical Manifestations

